Clinical trial
Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
NCT06064500
Study timeline
Registry last updated2025-03-10
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Small Cell Lung Cancerunresolved
Interventions
TarlatamabDRUG · verified · RxNorm: tarlatamab
Sponsors & collaborators
Amgenlead sponsor
Mapped research locations
JerusalemIsrael2Petah TikvaIsrael2New YorkNew York, United States1PhiladelphiaPennsylvania, United States1OmahaNebraska, United States1New HavenConnecticut, United States1Chapel HillNorth Carolina, United States1SpokaneWashington, United States1CharlottesvilleVirginia, United States1São PauloSão Paulo, Brazil1Porto AlegreRio Grande do Sul, Brazil1Miami BeachFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06064500 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.